Skip to Content

New Drug Approvals Archive - November 2014

See also: New Indications and Dosage Forms for November 2014

November 2014

Lemtrada (alemtuzumab) Injection

Date of Approval: November 14, 2014
Company: Genzyme
Treatment for: Multiple Sclerosis

Lemtrada (alemtuzumab) is a CD52-directed cytolytic monoclonal antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS).

Hysingla ER (hydrocodone bitartrate) Extended-Release Tablets

Date of Approval: November 20, 2014
Company: Purdue Pharma L.P.
Treatment for: Chronic Pain

Hysingla ER (hydrocodone) is a single-entity (without acetaminophen) extended-release opioid analgesic for around-the-clock management of moderate to severe chronic pain.

Onexton (benzoyl peroxide and clindamycin phosphate) Gel

Date of Approval: November 25, 2014
Company: Valeant Pharmaceuticals International, Inc.
Treatment for: Acne

Onexton (benzoyl peroxide and clindamycin phosphate) is an antimicrobial and lincosamide antibacterial combination for the once-daily topical treatment of acne vulgaris.

New Drug Approvals Archive

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.